These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29169562)

  • 41. The successful treatment with ixekizumab in a multi-failure psoriasis patient.
    Azevedo A; Torres T
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677837
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
    Woolf RT; Smith CH; Robertson K; Barker JN
    Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
    [No Abstract]   [Full Text] [Related]  

  • 43. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Secukinumab versus ustekinumab for skin clearance in patients with moderate to severe psoriasis after a year of treatment: Real-world practice.
    López Jiménez P; Suárez Pérez J; Herrera Acosta E; Aguilera Arjona J; Mendiola Fernández MV; Bosch García R; Herrera Ceballos E
    Dermatol Ther; 2019 Jul; 32(4):e12937. PubMed ID: 30983098
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents.
    Sobell JM; Kalb RE; Weinberg JM
    J Drugs Dermatol; 2009 Mar; 8(3):230-8. PubMed ID: 19271369
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
    Reich K; Burden AD; Eaton JN; Hawkins NS
    Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    JAMA Dermatol; 2021 Jan; 157(1):66-73. PubMed ID: 33263718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erythrodermic psoriasis treated with ustekinumab: an Italian multicenter retrospective analysis.
    Pescitelli L; Dini V; Gisondi P; Loconsole F; Piaserico S; Piccirillo A; Stinco G; Errichetti E; Talamonti M; Tripo L; Volpi W; Prignano F
    J Dermatol Sci; 2015 May; 78(2):149-51. PubMed ID: 25681953
    [No Abstract]   [Full Text] [Related]  

  • 49. Ocular toxoplasmosis in a patient treated with ustekinumab for psoriasis.
    Javadzadeh S; Gkini MA; Panos GD; Adewoyin T; Bewley A
    Clin Exp Dermatol; 2020 Aug; 45(6):802-804. PubMed ID: 32212270
    [No Abstract]   [Full Text] [Related]  

  • 50. Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study.
    Georgakopoulos JR; Lam K; Sandhu VK; Ighani A; Phung M; Piguet V; Yeung J
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e416-e418. PubMed ID: 32176394
    [No Abstract]   [Full Text] [Related]  

  • 51. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
    Georgakopoulos JR; Ighani A; Zhou LL; Yeung J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e32-e34. PubMed ID: 28695989
    [No Abstract]   [Full Text] [Related]  

  • 52. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience.
    Cannavò SP; Postorino E; Aragona E; Bartolotta A; Papaianni V; Guarneri C
    J Dermatolog Treat; 2018; 29(sup1):9-11. PubMed ID: 30247938
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies.
    Rallis E; Verros CD
    Dermatol Online J; 2011 Apr; 17(4):14. PubMed ID: 21549089
    [No Abstract]   [Full Text] [Related]  

  • 55. Recalcitrant psoriasis responding to new bilogic drug: ustekinumab.
    Husein-ElAhmed H; Molina-Leyva A; Garrido-TorresPuchol V; Ruiz-Carrascosa J
    Ann Saudi Med; 2013; 33(6):632-3. PubMed ID: 24413873
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy of ustekinumab in palmoplantar pustulosis.
    Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Uthurriague C; Paul C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):e204-e206. PubMed ID: 29194805
    [No Abstract]   [Full Text] [Related]  

  • 57. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.
    Dogra S; Bishnoi A; Narang T; Handa S
    Dermatol Ther; 2018 Jul; 31(4):e12611. PubMed ID: 29687662
    [No Abstract]   [Full Text] [Related]  

  • 58. Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment.
    Yeh NL; Hsu CY; Tsai TF; Chiu HY
    Clin Drug Investig; 2019 Dec; 39(12):1195-1203. PubMed ID: 31549347
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ustekinumab.
    Weber J; Keam SJ
    BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent.
    Bertrand V; El Haite A; Carré D
    Pediatr Dermatol; 2017 Jul; 34(4):e214-e215. PubMed ID: 28436109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.